Mechanism of traditional drug treatment of cancer-related ascites: through the regulation of IL-6/JAK-STAT3 pathway
Journal of Pharmacy and Pharmacology · 2025
DOI: 10.1093/jpp/rgae111 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmacy and Pharmacology, 2025. Verfasst von Yehan Sun und 6 weiteren Autor:innen. Beteiligte Einrichtung: Graduate School of Anhui University of Traditional Chinese Medicine, Hefei, People's Republic of China. Hauptthemen laut MEDLINE: STAT3 Transcription Factor, Ascites, Drugs, Chinese Herbal, Interleukin-6. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben.
Abstract (Originalsprache)
Context
Our clinical observation found that JiJiaoLiHuang Pill (JJLH), a classic traditional Chinese medicine (TCM) formulation, can significantly reduce the abdominal circumference of patients with malignant ascites, increase urine output, and improve the quality of life of patients, with preliminary efficacy. But, the exact mechanism is not yet clear.
Objective
Based on the above observations, the potential mechanism of action of the treatment was preliminarily explored.
Methods
We identified active ingredients by constructing a “Chinese medicine ingredient-key target-target” network, and verified them by molecular docking using AutoDock tools and PyMOL. Finally, we conducted preliminary verification of the validated pathways and targets using a mouse model of liver cancer ascites.
Results
Network pharmacology analysis obtained the top five active ingredients were quercetin, EUPATIN, kaempferol, Obtucarbamate B, and isorhamnetin and the top five key genes were SRC, HSP90AA1, MAPK1, STAT3, and PIK3CA. Molecular docking showed that all 5 active compounds were closely bound to key target genes (binding energy <−6). The animal experiment results showed that JJLH can significantly reduce abdominal circumference, increase urine output, and exhibit dose-dependent inhibition of the AQP-3/JAK-STAT-3 signaling pathway and the expression of related inflammatory factors.
Conclusions
The JJLH potentially inhibits the recurrence of liver cancer malignant ascites through the AQP-3/JAK-STAT-3 pathway and affects the prognosis of MA patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Graduate School of Anhui University of Traditional Chinese Medicine, Hefei, People's Republic of China.
- The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), HangZhou, People's Republic of China.
- Experimental Center of Clinical Research, Scientific Research Department, The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, People's Republic of China.
- Department of Biochemistry and Molecular Biology, School of Integrated Chinese and Western Medicine, Anhui University of Chinese Medicine, Hefei, People's Republic of China.
- The First Department of Oncology, The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, People's Republic of China.
ORCID-Profile: Xingxing Huo, Yongfu Zhu
Zitieren
APA
Sun, Y., Zhang, P., Ma, J., Chen, Y., Huo, X., Song, H., & Zhu, Y. (2025). Mechanism of traditional drug treatment of cancer-related ascites: through the regulation of IL-6/JAK-STAT3 pathway. Journal of Pharmacy and Pharmacology. https://doi.org/10.1093/jpp/rgae111
Vancouver
Sun Y, Zhang P, Ma J, Chen Y, Huo X, Song H, et al. Mechanism of traditional drug treatment of cancer-related ascites: through the regulation of IL-6/JAK-STAT3 pathway. Journal of Pharmacy and Pharmacology. 2025. doi:10.1093/jpp/rgae111
BibTeX
@article{Sun2025,
author = {Sun, Yehan and Zhang, Pengcheng and Ma, Jia and Chen, Youmou and Huo, Xingxing and Song, Hang and Zhu, Yongfu},
title = {Mechanism of traditional drug treatment of cancer-related ascites: through the regulation of IL-6/JAK-STAT3 pathway},
journal = {Journal of Pharmacy and Pharmacology},
year = {2025},
doi = {10.1093/jpp/rgae111}
}
EUVIMED